SLIM: FFR Driven Complete Revascularization Versus Usual Care in NSTEMI Patients and Multivessel Disease
Study Details
Study Description
Brief Summary
To compare FFR guided complete revascularization during the index procedure with usual care in non-STEMI patients with multivessel disease.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
Background:
Patients with non-ST elevation myocardial infarction (non-STEMI), as compared with STEMI patients, have a higher risk profile, more often MVD and less favourable outcome. Recent studies showed that complete revascularization in STEMI patients is feasible and effective. However, there is no clear evidence regarding the role of complete coronary revascularization by PCI in patients with non-STEMI with MVD.
Objective:
To compare FFR guided complete revascularization during the index procedure with usual care in non-STEMI patients with multivessel disease.
Design:
Prospective, multicentre, 1:1 randomized, investigator initiated study.
Hypothesis:
FFR guided complete percutaneous revascularisation of all significant stenosis in the non-culprit lesion performed within the index PCI procedure will improve clinical outcomes compared to the usual care, guided by discretion of the physician.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Experimental: Ischemia driven revascularization In the ischemia driven complete revascularisation strategy group all flow limiting (FFR ≤ 0.80) lesions will receive treatment by PCI and stenting. The non-IRA PCI should be performed during the same intervention. Exceptions can be made for complex lesions where the operator estimates that the revascularisation procedure will require significant contrast overload, which may lead to deterioration of cardiac and renal function of the patient. |
Procedure: Ischemia driven revascularization
In the ischemia driven complete revascularisation strategy group all flow limiting (FFR ≤ 0.80) lesions will receive treatment by PCI and stenting during the index intervention
|
| Active Comparator: Usual care group In the randomised to usual care group the procedure will stop after the PCI of the culprit artery and the patient will be referred to his treating cardiologist and/ or heart team who will decide whether a staged PCI of the non- IRA artery should take place. If the treating cardiologist (after advise of the heart team) decides to perform the non-IRA PCI revascularisation, than such treatment should take place within six weeks from the primary PCI in order to count as a scheduled staged PCI procedure. |
Other: Usual care group
In the randomised to usual care group the procedure will stop after the PCI of the culprit artery and the patient will be referred to his treating cardiologist and/ or heart team who will decide whether a staged PCI of the non- IRA artery should take place. If the treating cardiologist (after advise of the heart team) decides to perform the non-IRA PCI revascularisation, than such treatment should take place within six weeks from the primary PCI in order to count as a scheduled staged PCI procedure.
|
Outcome Measures
Primary Outcome Measures
- The incidence of MACE at 12 months [12 months]
MACE = The composite endpoint of all cause death, non-fatal Myocardial Infarction, any revascularisation and stroke at 12 months.
Secondary Outcome Measures
- The incidence of MACE in subgroups at 12 and 24 months. [12 and 24 months]
Prespecified subgroup analyses of primary outcomes will be performed for: Diabetic patients versus non-diabetic patients Elderly (≥ 75 years) versus young patients (< 75 years) Male versus Female gender High versus low risk patients according to GRACE Risk Score Patients previous myocardial infarction versus patients with no previous myocardial infarction The Global Registry of Acute Coronary Events (GRACE) score estimates the admission 6 month mortality for patients with acute coronary syndrome. The GRACE score ranges from 0 to > 285. A higher GRACE represents a higher mortality risk, ranging from 0-2% when the GRACE is between 0 and 87, to 99% when the GRACE exceeds 285.
- Composite endpoint of Net Adverse Clinical Events (NACE) defined as composite endpoint of Cardiac death, Myocardial Infarction, any Revascularisation, Stroke and major bleeding at 12, 24 and 36 months. [12, 24 and 36 months]
- Composite endpoint hospitalisation for heart failure and unstable angina pectoris at 12, 24 and 36 months. [12, 24 and 36 months]
- All-cause mortality or Myocardial infarction at 12, 24 and 36 months. [12, 24 and 36 months]
- Any revascularisation at 12, 24 and 36 months. [12, 24 and 36 months]
- Stent thrombosis at 12, 24 and 36 months. [12, 24 and 36 months]
- Bleeding (major and minor) at 48 hours and 12 months. [48 hours and 12 months]
- The incidence of MACE at 36 months as well as outcomes of each component of MACE at 12 and 24 and 36 months. [12, 24 and 36 months]
MACE = The composite endpoint of all cause death, non-fatal Myocardial Infarction, any revascularisation and stroke at 12 months.
- Left ventricular ejection fraction at 12 and 24 and 36 month (MIBI scan, MRI or Echocardiography). [12, 24 and 36 months]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Patients aged between 18-85 years presenting with non-STEMI according to current guidelines, who will be treated with PCI of the culprit and have at least one stenosis of >50% in a non-IRA on QCA or visual estimation of baseline angiography and judged feasible for treatment with PCI by the operator.
-
Non-IRA stenosis amenable for PCI treatment (operator's decision)
-
Signed informed consent
Exclusion Criteria:
-
Left main disease (stenosis > 50%)
-
Chronic total occlusion of a non-IRA
-
Indication for or previous coronary artery bypass grafting
-
Uncertain culprit lesion
-
Complicated IRA treatment, e.g. extravasation, permanent no re-flow after IRA treatment (TIMI flow 0-1) and inability to implant a stent
-
Known severe cardiac valve dysfunction that will require surgery or TAVI in the follow-up period.
-
Killip class III or IV during the completion of culprit lesion treatment.
-
Life expectancy of < 1 year.
-
Intolerance to Aspirin, Clopidogrel, Prasugrel, Ticagrelor or Heparin.
-
Gastrointestinal or genitourinary bleeding within the prior 3 months.
-
Planned elective surgical procedure necessitating interruption of thienopyridines during the first 6 months post enrolment.
-
Patients who are actively participating in another drug or device investigational study, which have not completed the primary endpoint follow-up period.
-
Pregnancy
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Gottsegen György Országos Kardiológiai Intézet | Budapest | Hungary | ||
| 2 | Bacs-Kiskun Teaching Hospital | Kecskemét | Hungary | ||
| 3 | Szeged University | Szeged | Hungary | ||
| 4 | Jeroen Bosch Ziekenhuis | Den Bosch | Netherlands | ||
| 5 | Zuyderland MC | Heerlen | Netherlands | ||
| 6 | Maastricht University Medical Centre | Maastricht | Netherlands | ||
| 7 | Viecuri Medisch Centrum | Venlo | Netherlands |
Sponsors and Collaborators
- Zuyderland Medisch Centrum
- Maastricht University Medical Center
- Radboud University Medical Center
- Jeroen Bosch Ziekenhuis
- VieCuri Medical Centre
- Gottsegen György Országos Kardiológiai Intézet
- Bács-Kiskun County Teaching Hospital
Investigators
- Principal Investigator: Saman Rasoul, Dr., Zuyderland MC
- Study Director: Arnoud van 't Hof, Prof. Dr., Zuyderland MC
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- 17-T-142
- 28708